How Long After Stopping Depo-Provera Can Meningioma Develop?

The question keeps coming up in consultations and online support groups: "I stopped taking Depo-Provera five years ago. Can I still get a meningioma from it?" The medical answer is complicated, and the legal answer may surprise you. Stopping the shot does not reset the clock on risk.

The Latency Problem

Brain tumors don't develop overnight. A meningioma that shows up on a 2025 MRI didn't start growing in 2025. Meningiomas are notoriously slow-growing, typically doubling in volume over years rather than months. By the time a tumor is large enough to cause symptoms — or large enough to be visible on imaging — it has usually been growing for some time.

That creates a disconnect that's central to both the science and the litigation. A woman who stopped Depo-Provera in 2015 might have her meningioma diagnosed in 2024. The ten-year gap doesn't mean the drug isn't responsible. It may simply mean that's how long the tumor took to grow.

The biological mechanism explains this. MPA binds to progesterone receptors expressed in meningioma cells. During prolonged Depo-Provera use, elevated MPA concentrations can stimulate receptor-positive tumor cells to proliferate. Once established, a tumor has its own growth dynamics. It doesn't necessarily stop when the drug does.

What the Research Shows

The most rigorous data on the post-discontinuation risk window comes from the same French population studies that influenced the FDA's 2024 action.

The landmark BMJ study published February 28, 2024 (Peyre et al., BMJ 2024;384:e076604) examined 18,061 women diagnosed with intracranial meningioma between 2009 and 2018, compared against 90,305 matched controls from the French National Health Insurance database. The findings on timing are striking:

Women who had discontinued injectable MPA within the prior 12 months still showed elevated meningioma risk. The risk was lower than in current users, but still significantly above baseline. Importantly, the study found that cumulative dose — not just current use — was the dominant predictor.

An earlier French study published in Neurochirurgie in 2018 documented cases of meningioma growth during high-dose progestogen therapy and subsequent tumor regression after cessation, but also cases where tumors stabilized or continued growing after stopping. The outcomes were not uniform.

A 2021 analysis in the Journal of Neuro-Oncology reviewed progestogen-associated meningiomas specifically and found that 34% of patients who stopped progestogen therapy experienced tumor regression, while the remainder required surgery. Regression, when it occurred, typically began within 6 to 18 months of discontinuation — but was not guaranteed.

Symptom Timeline: What Women Typically Experience

Symptoms of a meningioma don't usually announce themselves all at once. The typical progression follows a pattern, though it varies based on tumor location, size, and growth rate.

Phase 1: Subtle, dismissible symptoms (months to years before diagnosis)

Mild, recurring headaches that don't respond to over-the-counter medication. Occasional vision blurring or double vision, often attributed to eye strain or stress. Slight memory problems, sometimes chalked up to aging or workload. These symptoms are easy to ignore, and easy for physicians to attribute to other causes.

Phase 2: Escalating neurological symptoms

Persistent headaches that worsen with position changes. More pronounced vision changes, sometimes including field cuts (portions of visual field become blank or distorted). Hearing loss or ringing in one ear. Facial numbness. Weakness or clumsiness in one arm or leg. Seizures in some cases.

Phase 3: Imaging and diagnosis

A brain MRI or CT scan typically reveals the tumor at this stage, often leading to neurosurgical consultation. For tumors associated with progestogen use, the locations are somewhat predictable: skull base, convexity (outer surface of the brain), and the falx (the dividing structure between brain hemispheres) are most common.

The average time from first symptom to meningioma diagnosis in the published literature ranges from 12 to 36 months. That's a long time to be told your headaches are stress-related.

For a complete symptom guide, see our meningioma overview page.

Does Meningioma Shrink After Stopping Depo-Provera?

Sometimes. The evidence here is mixed, and context-dependent.

Several French neurosurgical case series documented cases where women with progestogen-associated meningiomas who stopped their medication showed partial or even near-complete tumor regression on repeat imaging. One series published in Acta Neurochirurgica (2016) described 7 women who avoided surgery after progestogen cessation and showed tumor volume reduction averaging 58% over 24 months of follow-up.

But the flip side is important: not all tumors regress, and regression is rarely complete. Tumors that were actively causing neurological symptoms (vision loss, hearing loss, facial weakness) often required surgery regardless of whether the progestogen was discontinued. And some tumors showed no volume change despite cessation.

The practical implication: stopping Depo-Provera after a meningioma diagnosis may be part of the medical management plan, but it is not a substitute for imaging follow-up and specialist consultation. Women should not interpret "tumor regression is possible" as meaning they can skip the neurologist.

Why the Timeline Matters Legally

The latency between Depo-Provera use and meningioma diagnosis has direct legal consequences.

Statutes of limitations. Most states give plaintiffs 2 to 3 years from the date they "discovered" their injury to file suit. For Depo-Provera meningioma cases, discovery typically means the date of diagnosis, or the date the plaintiff reasonably could have connected their diagnosis to the drug. The August 2024 FDA warning is a significant milestone in that timeline: for many women, it was the first time they had a medically official connection between their drug use and their brain tumor.

Proof of causation. Defense attorneys will argue that a woman who stopped Depo-Provera in 2012 and was diagnosed in 2023 can't establish that the drug caused her tumor. Plaintiffs' experts will counter with the latency data from the French cohort studies — showing that cumulative exposure, not recency of use, is the key variable. The research on post-discontinuation risk is part of the scientific foundation for those arguments.

Damages. Women who underwent neurosurgery, radiation, or who have ongoing neurological deficits face significant future medical costs. The timeline between exposure and diagnosis often spans decades, meaning women may have made family planning decisions, career decisions, and health decisions without knowledge of their elevated risk. That informational harm is part of what plaintiffs argue they're owed compensation for.

To understand where the litigation stands right now, read our April 2026 MDL 3140 update. And if you're wondering whether the FDA warning in 2024 changes your options, the FDA warning breakdown covers that in detail.

Related Resources

• What Is a Meningioma? Symptoms, Causes, Treatment
• Full Depo-Provera Side Effects List
• What the FDA's 2024 Warning Means for You
• MDL 3140 Litigation Update: April 2026
• How to File a Depo-Provera Claim

Frequently Asked Questions